| 摘要 |
The invention discloses compositions and methods for increasing chemotherapeutic specificity to endocrine dependent cancers, and reducing systemic toxicity, through administration of endocrine hormones in conjunction with administration of phase specific chemotherapeutics. The invention also discloses why prior art phase specific chemotherapeutic regimens fail to achieve high cure rates for cancer. The failure relates to the Gompertzian acceleration, or reduction in cancer cell cycle time, induced by the chemotherapeutic reduction of tumor size, which in turn results in the cancer's lack of phase synchronicity to subsequent administrations of the phase specific chemotherapeutic(s). The invention discloses how to avoid this failure in endocrine dependent cancers by using endocrine blockers between chemotherapeutic administrations to halt the cancer cells from passing the S-Phase and then using endocrine hormones to restart and accelerate S-Phase progression in conjunction with administration of appropriate phase specific chemotherapeutic(s).
|
